Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Complementary DNA was synthesized from 1 g of total RNA through reverse transcription
See our shipping policy and full disclaimer
These characteristics are consistent with its identity as a small linear peptide rather than a cyclized or cross-linked peptide structure
Examples: Sermorelin, gonadorelin, GHK-Cu (topical only), VIP (vasoactive intestinal peptide), NAD+
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
According to FDA labeling for semaglutide products, the incidence of gastrointestinal adverse events typically decreases over time with continued treatment at the same dose level
